Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals to Participate in June Investor Conferences
04:30pm, Wednesday, 27'th May 2026
ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
01:10am, Wednesday, 13'th May 2026
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
12:50pm, Tuesday, 12'th May 2026
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
05:00pm, Wednesday, 06'th May 2026
ROCKVILLE, Md. , May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
05:00pm, Wednesday, 06'th May 2026
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
10:21pm, Tuesday, 05'th May 2026
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:01pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.
Supernus Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
11:21am, Wednesday, 29'th Apr 2026
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
04:15pm, Wednesday, 22'nd Apr 2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.
05:42am, Monday, 13'th Apr 2026
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on April 07th, the Representative disclo
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average – Should You Sell?
03:43am, Wednesday, 08'th Apr 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
05:44am, Monday, 30'th Mar 2026
JPMorgan Chase and Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 45.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The ins
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Consensus PT from Brokerages
03:32am, Monday, 30'th Mar 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Two res
